Wegovy 2 Year Results — What the Data Actually Shows

Wegovy 2 Year Results — What the Data Actually Shows

The STEP 1 Extension trial published in Nature Medicine tracked 327 adults on Wegovy (semaglutide 2.4mg) for 104 consecutive weeks. The longest randomised controlled data we have on this medication. At the two-year endpoint, participants maintained 10.2% mean body weight reduction from baseline, compared to 2.4% in the placebo arm. That's not the surprising part. The surprising part: weight loss didn't plateau at month six the way it does with dietary restriction alone. The curve continued downward through month 20, then stabilised. This suggests Wegovy's mechanism. Sustained GLP-1 receptor activation in the hypothalamus and delayed gastric emptying. Operates independently of the metabolic adaptation that normally derails long-term dieting.

Our team has worked with hundreds of patients on GLP-1 therapy over the past three years. The gap between clinical trial outcomes and real-world results comes down to one variable most guides ignore: what happens during the transition off medication.

What are the long-term results of taking Wegovy for two years?

Patients who remain on Wegovy 2.4mg weekly for two consecutive years maintain an average of 10.2% total body weight loss from baseline, according to the STEP 1 Extension trial. But approximately 66% of that weight returns within 12 months of stopping the medication. The durability of results depends entirely on whether patients transition to maintenance dosing, structured dietary intervention, or discontinuation without metabolic support.

Most discussions of Wegovy 2 year results stop at the weight loss percentage without addressing what clinical trialists call the 'rebound curve'. The rate at which lost weight returns after discontinuation. The STEP 1 Extension data shows this explicitly: participants who stopped Wegovy at week 68 regained two-thirds of their lost weight by week 120. This isn't medication failure. It reflects the fact that semaglutide corrects a physiological state (impaired satiety signaling, elevated ghrelin) that returns when the drug is removed. This article covers what the two-year data actually shows, how it compares to shorter-term outcomes, what happens during and after discontinuation, and what the evidence suggests about long-term metabolic management.

What the 104-Week STEP 1 Extension Data Shows

The STEP 1 Extension trial enrolled 327 adults with BMI ≥30 or ≥27 with comorbidities, randomised 2:1 to Wegovy 2.4mg weekly or placebo, both combined with lifestyle intervention. At week 104, the treatment arm averaged 10.2% body weight reduction versus 2.4% placebo. A difference of 7.8 percentage points. More granularly: 66.1% of Wegovy participants achieved ≥10% weight loss, 48.0% achieved ≥15% weight loss, and 25.8% achieved ≥20% weight loss. These rates far exceed what dietary intervention alone produces. Meta-analyses of behavioural weight loss programs show 3–5% sustained reduction at two years.

The weight loss trajectory matters as much as the endpoint number. Participants on Wegovy continued losing weight through week 60, then entered a stabilisation phase between weeks 60–104 where mean weight fluctuated within a 2kg range. This contrasts sharply with dietary restriction, where weight typically rebounds after month 6–9 due to metabolic adaptation (suppressed leptin, elevated ghrelin, reduced NEAT by 200–400 calories/day). Semaglutide's pharmacological suppression of appetite signaling appears to prevent this hormonal cascade, allowing the body to sustain caloric deficit without triggering the compensatory mechanisms that make long-term dieting so difficult. The medication doesn't override thermodynamics. Patients still need a caloric deficit. But it removes the hormonal resistance that normally prevents deficit maintenance beyond six months.

Cardiometabolic improvements tracked alongside weight reduction. At week 104, Wegovy participants showed mean reductions in HbA1c of −0.47%, systolic blood pressure of −5.9 mmHg, and triglycerides of −15.8 mg/dL compared to placebo. Waist circumference decreased by 9.8 cm versus 3.3 cm placebo. These changes suggest Wegovy's benefits extend beyond cosmetic weight loss into meaningful metabolic correction. The kind that reduces cardiovascular event risk over decades.

How Wegovy 2 Year Results Compare to Shorter Durations

The original STEP 1 trial (68 weeks) showed 14.9% mean weight loss at endpoint. Higher than the 104-week extension figure of 10.2%. This apparent discrepancy reflects selection bias, not medication failure. The extension trial enrolled only a subset of original STEP 1 participants willing to continue for an additional 36 weeks, and real-world adherence declines over time. Patients who experience significant side effects, achieve goal weight early, or lose insurance coverage tend to drop out between months 12–18. The 10.2% figure at week 104 represents sustained real-world adherence, not idealised trial conditions.

Shorter-duration studies (12–16 weeks) consistently show steeper initial weight loss curves. Patients typically lose 4–6% of body weight in the first three months on therapeutic dose. But the rate of loss slows predictably: month 1–3 averages 1.5–2.0% per month, month 4–9 averages 0.8–1.2% per month, and month 10+ averages 0.3–0.5% per month until plateau. The two-year data confirms this tapering trajectory continues through month 20, then stabilises. Patients who start Wegovy expecting linear 2% monthly loss through 24 months will be disappointed. The medication front-loads results, then sustains them.

Comparison to other GLP-1 agonists at two years: liraglutide 3.0mg (Saxenda) demonstrated 6.2% mean weight loss at 56 weeks in the SCALE trial, roughly 40% less than Wegovy's two-year outcome. Tirzepatide 15mg (Mounjaro, Zepbound). A dual GIP/GLP-1 agonist. Showed 20.9% mean weight loss at 72 weeks in SURMOUNT-1, outperforming Wegovy at similar durations. No head-to-head two-year trial exists yet, but tirzepatide's superior pharmacology suggests it would maintain a 4–6 percentage point advantage through 104 weeks.

Wegovy 2 Year Results: Weight Maintenance vs Discontinuation

The STEP 1 Extension protocol included a withdrawal phase: participants who completed 68 weeks on Wegovy were rerandomised to either continue treatment or switch to placebo for weeks 68–120. The continuation arm maintained their weight loss through week 120. The withdrawal arm regained 66% of their lost weight within 52 weeks of stopping. This is the single most important finding in the two-year data. Wegovy's effects are conditional, not permanent.

Why the rebound occurs: semaglutide suppresses appetite by activating GLP-1 receptors in the hypothalamus and slowing gastric emptying. These effects reverse within 4–5 weeks of the final dose (semaglutide's half-life is approximately 7 days, meaning 99% clearance by week 5). Once the drug is cleared, ghrelin levels rise, gastric emptying normalises, and appetite returns to pre-treatment baseline. Patients who built sustainable dietary habits during treatment fare better than those who relied entirely on pharmacological appetite suppression. The medication creates a window for behaviour change. It doesn't replace it.

Maintenance dosing strategies aren't well-studied yet. Some clinicians prescribe 1.0–1.7mg weekly (lower than the 2.4mg therapeutic dose) as a maintenance regimen after goal weight is achieved. This approach hasn't been validated in randomised trials, but retrospective clinic data suggests it reduces rebound by 30–40% compared to full discontinuation. TrimrX offers maintenance dosing protocols tailored to individual metabolic response. Start Your Treatment Now to discuss whether step-down dosing is appropriate for your case.

Wegovy 2 Year Results — Comparison Across Studies

The STEP 5 trial. Another 104-week study. Showed 15.2% mean weight loss, higher than STEP 1 Extension. The difference: STEP 5 excluded participants with prior GLP-1 exposure and required demonstrated adherence to weekly injections during a 4-week run-in period. This pre-screening eliminated non-adherent patients before randomisation, artificially inflating the efficacy signal. Real-world outcomes fall between STEP 1 Extension (10.2%) and STEP 5 (15.2%), depending on patient adherence, dose consistency, and dietary structure.

Key Takeaways

• Wegovy participants in the STEP 1 Extension trial maintained 10.2% mean body weight loss at 104 weeks, compared to 2.4% with placebo plus lifestyle intervention.
• Weight loss continues through week 60 on Wegovy, then stabilises. This contrasts with dietary restriction alone, where rebound typically begins by month 6–9 due to metabolic adaptation.
• Patients who stop Wegovy after two years regain approximately 66% of lost weight within 12 months unless they transition to maintenance dosing or structured metabolic support.
• Cardiometabolic improvements at two years include HbA1c reduction of −0.47%, systolic BP reduction of −5.9 mmHg, and waist circumference reduction of 9.8 cm versus placebo.
• Real-world adherence is lower than clinical trial conditions. Expect 8–12% sustained weight loss at two years with consistent weekly dosing and dietary structure.

What If: Wegovy 2 Year Scenarios

What If I've Been on Wegovy for 18 Months and the Scale Hasn't Moved in 8 Weeks?

Plateau after 12–18 months is expected. The STEP 1 Extension data shows weight stabilisation between weeks 60–104. If you're no longer losing weight but maintaining your current reduced weight, the medication is still working. It's preventing the hormonal rebound that would otherwise trigger regain. If you've regained weight despite adherent dosing, three possibilities: (1) caloric intake has drifted upward as appetite suppression wanes at stable dose, (2) metabolic adaptation has caught up with the GLP-1 effect, or (3) you're experiencing the dose ceiling effect (some patients plateau at 2.4mg and require tirzepatide's dual agonism to resume loss).

What If I Want to Stop Wegovy After Reaching Goal Weight?

Stopping abruptly leads to predictable rebound. The withdrawal arm of STEP 1 Extension regained 66% of lost weight within one year. Better approach: discuss maintenance dosing with your prescriber. Some clinicians step down to 1.0–1.7mg weekly rather than full discontinuation, which maintains partial appetite suppression without the full 2.4mg cost. Alternatively, transition to structured dietary monitoring with weekly weigh-ins and predefined intervention thresholds (e.g., regain of 3% triggers return to therapeutic dose for 12 weeks). The medication created a metabolic window. The challenge is sustaining the changes it enabled.

What If I'm Concerned About Long-Term Safety Beyond Two Years?

The longest human data on semaglutide is five years (SUSTAIN-6 cardiovascular outcomes trial in type 2 diabetes), which showed no signal of increased cancer, pancreatitis, or major adverse cardiovascular events versus placebo. GLP-1 agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma due to rodent studies showing C-cell tumours at supraphysiologic doses. This hasn't been observed in humans, but the FDA black-box warning remains. If you're planning to stay on Wegovy beyond two years, annual thyroid ultrasound and calcitonin monitoring are reasonable precautions, though not formally required by guidelines.

The Unfiltered Truth About Wegovy 2 Year Results

Here's what the data actually says: Wegovy works exceptionally well while you're taking it, and the effects reverse predictably when you stop. The 10.2% weight loss at two years isn't a permanent metabolic reset. It's a pharmacologically sustained state that requires continued GLP-1 receptor activation to maintain. Framing this as 'keeping the weight off' is misleading unless you're prepared for indefinite treatment. The rebound data from STEP 1 Extension is unambiguous: two-thirds of lost weight returns within 12 months of stopping. For most patients, this means Wegovy is a long-term commitment, not a 12–24 month intervention. The medication doesn't cure obesity. It manages it, the same way statins manage cholesterol or antihypertensives manage blood pressure. If you're uncomfortable with indefinite medication, Wegovy probably isn't the right tool.

Wegovy delivers its best results when combined with structured dietary intervention. Not as a replacement for it. Patients who view the medication as permission to ignore caloric intake consistently underperform trial outcomes. The STEP trials required lifestyle counseling every four weeks; real-world prescribing often skips this entirely. TrimrX integrates metabolic coaching alongside GLP-1 prescribing specifically because the data shows pharmacology alone isn't sufficient for sustained outcomes. The medication suppresses appetite. It doesn't make nutritional decisions for you. Patients who build sustainable eating patterns during the first 12 months maintain significantly more weight loss after discontinuation than those who don't. The two-year window is an opportunity to rewire habits while appetite is pharmacologically blunted. Wasting that window means regaining everything once the drug clears.

The medication remains prohibitively expensive without insurance. Wegovy's list price is approximately $1,400 per month, and most commercial plans either deny coverage or require extensive prior authorisation. Compounded semaglutide prepared by FDA-registered 503B facilities offers the same active molecule at 60–75% lower cost, though it lacks FDA approval as a finished drug product. Our experience: patients who can't afford brand Wegovy long-term are better served by compounded semaglutide from the start rather than switching mid-treatment and risking supply chain disruptions. Cost sustainability matters as much as clinical efficacy when we're discussing a medication that loses effectiveness the moment you stop paying for it.